-
PurposeRetroviral vector containing human BAP1 C91A (catalytically inactive mutant) and Thy1.1 selection marker
-
Depositing Lab
-
Sequence Information
Full plasmid sequence is not available for this item.
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 81025 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneMSCV-IRES-Thy1.1 DEST
-
Backbone manufacturerRao lab (Addgene plasmid# 17442)
- Backbone size w/o insert (bp) 8200
- Total vector size (bp) 10400
-
Vector typeMammalian Expression, Retroviral
-
Selectable markersThy1.1
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameBAP1
-
SpeciesH. sapiens (human)
-
Insert Size (bp)2200
-
MutationBAP1 C91A (point mutation, catalytically inactive)
-
Entrez GeneBAP1 (a.k.a. HUCEP-13, KURIS, TPDS1, UBM2, UCHL2, UVM2, hucep-6)
- Promoter 5’LTR
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer pLXSN-5 (5'-CCCTTGAACCTCCTCGTTCGACC-3')
- 3′ sequencing primer IRES-R (5'-GCATTCCTTTGGCGAGAG-3') (Common Sequencing Primers)
Resource Information
-
Articles Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
BAP1 C91A was a gift from Anjana Rao (Addgene plasmid # 81025 ; http://n2t.net/addgene:81025 ; RRID:Addgene_81025) -
For your References section:
Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex. Balasubramani A, Larjo A, Bassein JA, Chang X, Hastie RB, Togher SM, Lahdesmaki H, Rao A. Nat Commun. 2015 Jun 22;6:7307. doi: 10.1038/ncomms8307. 10.1038/ncomms8307 PubMed 26095772